Literature DB >> 11295958

Dose discrepancies between the Physicians' Desk Reference and the medical literature, and their possible role in the high incidence of dose-related adverse drug events.

J S Cohen1.   

Abstract

BACKGROUND: Adverse drug events (ADEs) are a major cause of morbidity and mortality, and even minor ADEs may adversely affect patients' compliance with treatment. Because most ADEs are dose-related phenomena, adjusting drug dosages to account for individual patients' needs and tolerances is fundamental to good therapeutics.
OBJECTIVE: To determine whether the Physicians' Desk Reference (PDR), the leading source of drug information for physicians, provides the full range of effective drug doses, especially the lowest, least ADE-prone doses of medications, for physicians to consider in treating patients.
METHODS: Review of dosage guidelines and dose-response information in the PDR. Comparison with dose-response data obtained from articles listed in MEDLINE from 1966 to 2000.
RESULTS: For many types of medications, physicians are frequently advised to use the lowest effective doses of drugs, especially initially. Yet, effective low doses determined in prerelease studies or in postrelease work are often omitted from the PDR, even when they have been recommended by expert panels.
CONCLUSIONS: Optimal therapeutics depends on the availability of comprehensive information. However, the PDR contains only the limited dose information from package inserts. Because the PDR was originally developed as a promotional device, there is no mechanism by which all clinically relevant dose-response data or important postrelease discoveries are regularly and rapidly incorporated into it. Thus, a gap exists in the availability of current and comprehensive dose information for physicians. This article provides information on lower, effective doses for 48 major medications, with an extensive reference list-a compilation of low-dose information not previously published, to our knowledge, in the medical literature. Physicians must have a readily accessible source of current and complete dose-response information to individualize drug therapy and minimize the risks of ADEs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11295958     DOI: 10.1001/archinte.161.7.957

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  12 in total

Review 1.  Improving safety reporting from randomised trials.

Authors:  John P A Ioannidis; Joseph Lau
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

2.  Clinician use of a palmtop drug reference guide.

Authors:  Jeffrey M Rothschild; Thomas H Lee; Taran Bae; David W Bates
Journal:  J Am Med Inform Assoc       Date:  2002 May-Jun       Impact factor: 4.497

3.  Is bigger better? An argument for very low starting doses.

Authors:  James P McCormack; G Michael Allan; Adil S Virani
Journal:  CMAJ       Date:  2010-10-04       Impact factor: 8.262

Review 4.  Drug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II).

Authors:  Rashmi R Shah
Journal:  Br J Clin Pharmacol       Date:  2004-11       Impact factor: 4.335

Review 5.  The art and science of risk management: a US research-based industry perspective.

Authors:  Janice K Bush; Wanju S Dai; Gretchen S Dieck; Linda S Hostelley; Thomas Hassall
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 6.  Pharmacogenetics in drug regulation: promise, potential and pitfalls.

Authors:  Rashmi R Shah
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-08-29       Impact factor: 6.237

7.  Worldwide analysis of factors associated with medicines compendia publishing.

Authors:  Blanca Arguello; Fernando Fernandez-Llimos
Journal:  Int J Clin Pharm       Date:  2013-03-28

8.  Information deficits in the summary of product characteristics preclude an optimal management of drug interactions: a comparison with evidence from the literature.

Authors:  Verena Bergk; Walter E Haefeli; Christiane Gasse; Hermann Brenner; Meret Martin-Facklam
Journal:  Eur J Clin Pharmacol       Date:  2005-06-28       Impact factor: 2.953

Review 9.  Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing.

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

10.  Photocurable Bioink for the Inkjet 3D Pharming of Hydrophilic Drugs.

Authors:  Giovanny F Acosta-Vélez; Chase S Linsley; Madison C Craig; Benjamin M Wu
Journal:  Bioengineering (Basel)       Date:  2017-01-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.